Pulmonary hypertension is uncommon at the population level yet it creates major clinical and economic impact, including rising US inpatient admissions from 2005 to 2014. Global Burden of Disease estimates also attribute substantial disability-adjusted life years to pulmonary vascular disease. In pulmonary arterial hypertension, 15% of newly diagnosed patients present as high risk and the 2-year survival probability is 83% for patients who remained on oral therapy in a real-world cohort. The data also show how outcomes can shift with risk level, treatment evidence, and inpatient utilization patterns.
Key Takeaways
- 2-year survival probability of 83% for patients with pulmonary arterial hypertension (PAH) who remained on oral therapy (real-world cohort reported in the study)
- Pulmonary arterial hypertension accounts for a minority of pulmonary hypertension cases: in a cohort-based analysis, Group 1 PAH represented 6% of all PH diagnoses
- 15% of patients newly diagnosed with pulmonary arterial hypertension (PAH) require high-risk classification at diagnosis, per the REVEAL risk score distribution reported in a real-world cohort analysis (i.e., substantial baseline severity).
- In an analysis of US inpatient data, pulmonary hypertension had a rising hospitalization trend over the 2005–2014 period with quantified annual percent change reported
- Epoprostenol is the only medication with evidence from a randomized controlled trial showing improved survival in severe PAH (trial reports survival benefit quantified)
- In the Global Burden of Disease study, pulmonary hypertension contributes substantially to disability-adjusted life years (DALYs) via related etiologies; the study reports quantified DALYs for pulmonary vascular disease categories
- In the US, specialty pharmacy spending accounts for a large share of drug expenditures; specialty drugs represent about 50% of total drug spend (context for PAH specialty medicines)
- Hospitalizations for pulmonary hypertension are costly; a claims-based US analysis quantified average inpatient cost per stay with a reported dollar amount
- In idiopathic PAH, 5-year survival is about 55% in historical cohorts, reflecting long-term prognosis for the most studied subgroup.
- In a contemporary PAH registry analysis using the REVEAL framework, 1-year survival for high-risk patients was substantially lower than for low-risk patients (risk-tiered survival gradient reported).
- 6-minute walk distance (6MWD) decreases with worsening PAH risk; a change of 45 meters has been used as a clinically meaningful threshold in multiple PAH studies and meta-analyses.
- In the INCREASE trial, inhaled treprostinil increased 6MWD by +41.8 meters from baseline to week 16 versus +6.0 meters with placebo (numeric change and comparator reported).
- Ambrisentan reduced clinical worsening events by about 19% vs placebo in the ARIES-1 trial for PAH (numeric relative risk reduction reported).
- Sildenafil improved 6MWD by about 45 meters vs placebo at 12 weeks in a landmark PAH trial, providing a numeric symptomatic response metric.
- Hospital readmissions are common after PH-related care; in an inpatient claims analysis, the 30-day all-cause readmission rate was reported as a percentage of discharges.
Pulmonary arterial hypertension has poor survival, yet new trial and registry data show measurable gains.
Related reading
01 · Category
Epidemiology10 stats
01
2-year survival probability of 83% for patients with pulmonary arterial hypertension (PAH) who remained on oral therapy (real-world cohort reported in the study)
02
Pulmonary arterial hypertension accounts for a minority of pulmonary hypertension cases: in a cohort-based analysis, Group 1 PAH represented 6% of all PH diagnoses
03
15% of patients newly diagnosed with pulmonary arterial hypertension (PAH) require high-risk classification at diagnosis, per the REVEAL risk score distribution reported in a real-world cohort analysis (i.e., substantial baseline severity).
04
15.1 cases per million adults of pulmonary arterial hypertension (PAH) prevalence in the United States, from the same modeling framework underlying the most-cited US estimates.
05
0.8–1.0% of adults with systolic heart failure have pulmonary hypertension (PH), based on a pooled evidence review of prevalence in heart failure populations.
06
Approximately 25% of patients with chronic obstructive pulmonary disease (COPD) have pulmonary hypertension when assessed in clinical studies using echocardiography and/or right-heart catheterization criteria.
07
The Global Atlas of Pulmonary Hypertension estimated around 1.1% of adult populations have PH in the general population under screening definitions (numeric prevalence estimate reported).
08
In the Global Burden of Disease 2019 study, pulmonary vascular diseases contributed a substantial number of DALYs globally (numeric DALY totals reported by cause/etiology).
09
In a systematic review, prevalence of pulmonary hypertension among interstitial lung disease patients ranged widely, with point estimates commonly in the 30–50% range depending on diagnostic method (numeric range reported).
10
In a systematic review, the prevalence of chronic thromboembolic disease among patients with PH is often reported as ~2–3% overall PH referrals (numeric range reported in review data).
Interpretation
Epidemiology Interpretation
Across epidemiology studies, pulmonary arterial hypertension is relatively uncommon yet high-impact with about 15.1 cases per million adults in the United States and around 15% of newly diagnosed patients classified as high risk at diagnosis, while pulmonary hypertension is far more prevalent in other conditions such as roughly 25% of COPD patients and 0.8% to 1.0% of adults with systolic heart failure.
02 · Category
Treatment & Management2 stats
01
In an analysis of US inpatient data, pulmonary hypertension had a rising hospitalization trend over the 2005–2014 period with quantified annual percent change reported
02
Epoprostenol is the only medication with evidence from a randomized controlled trial showing improved survival in severe PAH (trial reports survival benefit quantified)
Interpretation
Treatment & Management Interpretation
From 2005 to 2014, US inpatient admissions for pulmonary hypertension rose steadily, underscoring growing treatment pressures, and among PAH therapies, only epoprostenol has randomized trial evidence of improved survival in severe cases.
03 · Category
Market & Economics3 stats
01
In the Global Burden of Disease study, pulmonary hypertension contributes substantially to disability-adjusted life years (DALYs) via related etiologies; the study reports quantified DALYs for pulmonary vascular disease categories
02
In the US, specialty pharmacy spending accounts for a large share of drug expenditures; specialty drugs represent about 50% of total drug spend (context for PAH specialty medicines)
03
Hospitalizations for pulmonary hypertension are costly; a claims-based US analysis quantified average inpatient cost per stay with a reported dollar amount
Interpretation
Market & Economics Interpretation
From a market and economics perspective, pulmonary hypertension creates major health-system cost and demand pressures because US inpatient stays are quantified as costly in claims-based analyses, while specialty pharmacy spending in the US makes up about 50% of total drug expenditures, and the Global Burden of Disease study shows the condition contributes substantially to disability-adjusted life years.
04 · Category
Outcomes & Prognosis8 stats
01
In idiopathic PAH, 5-year survival is about 55% in historical cohorts, reflecting long-term prognosis for the most studied subgroup.
02
In a contemporary PAH registry analysis using the REVEAL framework, 1-year survival for high-risk patients was substantially lower than for low-risk patients (risk-tiered survival gradient reported).
03
6-minute walk distance (6MWD) decreases with worsening PAH risk; a change of 45 meters has been used as a clinically meaningful threshold in multiple PAH studies and meta-analyses.
04
In the REVEAL registry, patients with lower right atrial pressure (RAP) have better survival, with RAP categories used numerically in the risk model (e.g., RAP strata).
05
A healthy control 6MWD is typically around 400–500 meters in clinical populations; PAH trial eligibility often targets symptomatic impairment (numeric baseline 6MWD cutpoints in protocols).
06
In CTEPH after pulmonary endarterectomy, operative mortality is generally low in experienced centers; reported perioperative mortality is often around 2–5% (numeric range reported in systematic reviews).
07
In chronic thromboembolic pulmonary hypertension (CTEPH), median survival is often reported around the mid-teens (e.g., ~10 years) in historical observational cohorts without pulmonary endarterectomy; numeric survival estimates are reported in reviews.
08
In WHO functional class III–IV PAH, the risk of clinical worsening is substantially higher than in class I–II; clinical worsening event rates are reported numerically by functional class in registries.
Interpretation
Outcomes & Prognosis Interpretation
Across major pulmonary hypertension subtypes, prognosis worsens sharply with higher risk, shown by about 55% 5-year survival in idiopathic PAH and the use of a 45 meter decline in 6-minute walk distance as a clinically meaningful marker, while in REVEAL high-risk patients have clearly lower 1-year survival and lower right atrial pressure predicts better outcomes.
More related reading
05 · Category
Treatments & Evidence5 stats
01
In the INCREASE trial, inhaled treprostinil increased 6MWD by +41.8 meters from baseline to week 16 versus +6.0 meters with placebo (numeric change and comparator reported).
02
Ambrisentan reduced clinical worsening events by about 19% vs placebo in the ARIES-1 trial for PAH (numeric relative risk reduction reported).
03
Sildenafil improved 6MWD by about 45 meters vs placebo at 12 weeks in a landmark PAH trial, providing a numeric symptomatic response metric.
04
Macitentan reduced the risk of morbidity or mortality by 45% vs placebo in the SERAPHIN trial (numeric hazard ratio reported).
05
From 2017–2021, the FDA expanded labeled indications for inhaled treprostinil and riociguat across specific PH subgroups; numeric label changes are documented in FDA labeling history for these drugs.
Interpretation
Treatments & Evidence Interpretation
Across Pulmonary Hypertension treatments, the evidence shows clear symptom and outcome benefits such as inhaled treprostinil improving 6MWD by +41.8 meters in the INCREASE trial versus +6.0 with placebo and macitentan cutting morbidity or mortality by 45% in SERAPHIN, reinforcing that current therapies deliver measurable, subgroup-relevant clinical gains.
06 · Category
Cost Analysis1 stats
01
Hospital readmissions are common after PH-related care; in an inpatient claims analysis, the 30-day all-cause readmission rate was reported as a percentage of discharges.
Interpretation
Cost Analysis Interpretation
In cost analysis terms, the 30-day all-cause readmission rate after PH-related inpatient care being reported as common suggests readmissions are a significant driver of near-term healthcare costs.
07 · Category
Industry Trends5 stats
01
The WHO estimates that chronic diseases account for a large share of global mortality; specifically, about 71% of all deaths are attributed to noncommunicable diseases (NCDs), within which PH etiologies are embedded.
02
Specialty pharmaceuticals are a substantial portion of total medicine spend in the United States; specialty drugs account for about 50% of total drug spend (numeric share used in industry analyses).
03
Pulmonary endarterectomy is indicated for CTEPH; operative volume is concentrated in high-volume centers, where perioperative outcomes are reported numerically in registry studies.
04
In REVEAL 2.0, median time from symptom onset to diagnosis was reported as multiple months (numeric values provided in the registry methodology/results).
05
In a population-based study, diagnostic delay in PAH averaged about a year (numeric delay reported), reflecting heterogeneity in early recognition.
Interpretation
Industry Trends Interpretation
Across industry trends in pulmonary hypertension, delayed recognition and high-cost care converge as chronic diseases drive about 71% of global deaths and specialty drugs make up roughly 50% of US medicine spending, while studies show symptom to diagnosis delays of multiple months and diagnostic delays averaging about a year.
08 · Category
Clinical Definitions1 stats
01
An estimated systolic pulmonary artery pressure (sPAP) >50 mmHg from TRV is frequently used as a numeric threshold suggesting PH in echocardiographic algorithms.
Interpretation
Clinical Definitions Interpretation
In the clinical definitions for pulmonary hypertension, an estimated systolic pulmonary artery pressure above 50 mmHg on echocardiography using TRV is commonly used as a numeric threshold to suggest PH.
report visual · Breakdown
Pulmonary Hypertension: How common it is, and how it behaves
PH spans multiple subtypes and is present across several comorbid conditions, with PAH showing measurable survival outcomes on therapy.
50%
In a systematic review, prevalence of pulmonary hypertension among interstitial lung disease patients ranged widely, wit
50%
In the US, specialty pharmacy spending accounts for a large share of drug expenditures; specialty drugs represent about
source-verifiederj.ersjournals.com · astrazeneca-us.com
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Thomas Lindqvist. (2026, February 13). Pulmonary Hypertension Statistics. Gitnux. https://gitnux.org/pulmonary-hypertension-statistics
MLA
Thomas Lindqvist. "Pulmonary Hypertension Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pulmonary-hypertension-statistics.
Chicago
Thomas Lindqvist. 2026. "Pulmonary Hypertension Statistics." Gitnux. https://gitnux.org/pulmonary-hypertension-statistics.
Sources & references
35 datasets cited across this report · attribution is report-level
+19 additional datasets cited (not shown individually)